US/UK/Canada

Share

About Us

Curasight is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and treatment in multiple cancer types, most notably for brain and prostate cancer.

Pick a time period -
Tags ( Active)

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial

The partnership deal closed with Curium last year marks the most important milestone for Curasight to date. Now, the European Medicines Agency (EMA) has approved the clinical trial application for the phase II study with uTRACE in prostate cancer. – The acceptance illustrates the strong progress being made in developing uTRACE, CEO Ulrich Krasilnikoff comments.Read the full article at biostock.se: https://www.biostock.se/en/2024/04/curasight-gets-green-light-from-ema-in-phase-ii-prostate-cancer-trial/ This is a press release from BioStock - Connecting Innovation & Capital. https://

Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients

· Dosing of first patient expected 2Q 2024 · CTA approval marks progress in development of uTRACE[®] in prostate cancer under the collaboration between Curasight and Curium Inc. · Phase 2 trial is part of Curasight’s efforts to build a pipeline of products using radiopharmaceuticals for improved diagnosis and more targeted treatment of different cancer types  Copenhagen, April 16, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced approval of clinical trial application (CTA) from the European Medicines

Curasight announces change in the Board of Directors

Copenhagen, April 12, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS)  announces that the chairperson of the Board of Directors, Per Falholt, has today announced that he wishes to step down from the Board of Directors with immediate effect. Kirsten Drejer has been elected as the new chairperson of the Board of Directors.Per Falholt, the Chairperson of the Board of Directors, has notified Curasight that he wishes to step down for the Board of Directors with effect from today due to personal reasons. In continuation of this, an extraordinary board meeting has been held,

Resolutions of the Annual General Meeting 2024 of Curasight A/S

Copenhagen, Denmark, 21 March 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, DenmarkToday, the shareholders in Curasight passed the following resolutions at the Annual General Meeting in accordance with the agenda: 1. The Board of Directors’ report on the Company’s activities in the preceding financial year The general meeting toke note of the Board of Directors’ report on the Company’s activities in 2023. 2. Presentation and approval of the annual report

BioStock: Curasight cancels rights issue and evaluates alternative financing

In mid February, Curasight announced a DKK 51.2 million rights issue to accelerate clinical development of uTREAT and uTRACE. Now, about a month later, the company has decided to cancel the rights issue and is evaluating alternative sources of financing. Following the announcment, the share price traded down.Read the full article at biostock.se: https://www.biostock.se/en/2024/03/curasight-cancels-rights-issue-and-evaluates-alternative-financing/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Curasight not to proceed with rights issue; evaluating alternative financing opportunities

Copenhagen, Denmark, 11 March 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announces today it will not proceed with the Rights Issue announced on February 13[th] 2024 (“Rights Issue”). The Board of Directors took the decision following a less than optimal participation in the Rights Issue by shareholders due to the current challenging market conditions and the fact that Curasight’s share price is trading below the offer price in the Rights Issue. The Company remains committed to accelerating its therapeutic strategy and is currently evaluating alternative financing

Notice of Annual General Meeting 2024

The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) on Thursday 21 March 2024 at 10:00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.Agenda 1. The Board of Directors’ report on the Company’s activities in the preceding financial year 2. Presentation and approval of the annual report 3. Appropriation of profit or covering of loss as recorded in the adopted annual report 4. Election of members to the Board of Directors 5. Election

The subscription period in Curasight’s rights issue begins today

Copenhagen, Denmark, 23 February 2024 - Today is the first day of the subscription period in Curasight A/S’s ("Curasight" or the “Company" – TICKER: CURAS) new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"), which was resolved by the Board of Directors on 13 February 2024.Summary of the Rights Issue · Each existing share in the Company, as of the record date on 22 February 2024, entitles the holder to one (1) subscription right. Seven (7) subscription rights entitle the holder to

Curasight publishes information memorandum in connection with forthcoming rights issue

Copenhagen, Denmark, 22 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has prepared and published an information memorandum (the “Information Memorandum”) relating to the new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"), which was resolved by the Board of Directors on 13 February 2024. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com, www.nordic-issuing.se, www.redeye.se).

Annual Report for the fiscal year 2023

Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal year of 2023. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report."2023 was a busy year for Curasight where we made significant progress on our mission to revolutionize cancer care. Our theranostics approach for improved diagnosis and treatment options for certain cancers was supported by the announcement of preclinical data using our therapeutic platform uTREAT[®]

Year-end report October – December 2023

Business Highlights during the fourth quarter 2023 · Encouraging preclinical data using uTREAT in non-small cell lung cancer · Announcing the submission of the clinical trial application to the European Medicines Agency for the investigation of uTRACE in a phase 2 trial · Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the the Year-end report October – December 31, 2023. The Year-end report is available as

BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise

Last year, a lot of focus for Curasight revolved around prostate cancer and the licensing deal with Curium. Now, the company has announced the next step for the theranostic approach and its wish to accelerate clinical development of both uTREAT and uTRACE in parallel. Curasight aims at starting a phase I/IIa basket trial in several indications and in order to finance this updated develoment strategy, the company aims at raising DKK 51.2 million in a rights issue. BioStock contacted CEO Ulrich Krasilnikoff to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2024/

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"). The proceeds are intended to be used to strengthen the Company’s capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types, as well as to strengthen Curasight’

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

· Coming Phase I/IIa basket trial planned to include five select cancer indications · Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE[®]) and therapy (uTREAT[®]) · First patients expected to be dosed in the beginning of 2025 with expected first efficacy data in 2025. Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer

BioStock: Curasight gets first milestone payment from Curium

The prostate cancer partnership with Curium marks the most pivotal moment for the radiopharmaceutical focused biotech company Curasight to date. Now, the company has announced a first milestone payment under the deal, for the validation of GMP manufacturing of finished product. BioStock reached out to CEO Ulrich Krasilnikoff to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2024/02/curasight-gets-first-milestone-payment-from-curium/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

· USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE[®] for use in prostate cancer between Curasight A/S and Curium Inc. · Milestone relates to the validation of GMP manufacturing of finished product and illustrates progress in the development plan for uTRACE[®] PET imaging technology · Under the agreement signed in 2023 Curasight is eligible to receive up to mUSD 70 in development milestones plus additional commercial milestones and double-digit royalties on sales upon commercialization

BioStock: Curasight gears up for phase II study in prostate cancer

Following the Curium deal this spring, Curasight has now submitted a clinical trial application and selected a CRO to carry out a phase II trial with uTRACE. The trial intends to evaluate the uTRACE for the diagnosis of prostate cancer patients. BioStock contacted Curasight CEO Ulrich Krasilnikoff to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2023/12/curasight-gears-up-for-phase-ii-study-in-prostate-cancer/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients

· Company on track to dose first patient in 2Q 2024 · CTA marks progress in development of uTRACE[®] in prostate cancer under the collaboration between Curasight and Curium Copenhagen, December 18, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced submission of clinical trial application (CTA) to the European Medicines Agency (EMA) for the investigation of uTRACE® in a phase 2 trial as a non-invasive alternative or supplement to traditional biopsies in prostate cancer patients in active surveillance.The CTA was submitted under the new application

Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer

· Phase 2 study is part of the collaboration between Curasight and Curium announced earlier this year · Appointment of clinical CRO marks further step in progress in development of uTRACE as a potential new diagnostic solution for prostate cancer Copenhagen, December 13, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced it has signed an agreement with ABX-CRO, an experienced international clinical research organization serving the pharmaceutical industry, to run the phase 2 study investigating uTRACE[®] in improving the diagnosis of prostate cancer.

BioStock: Curasight CEO: “Working on accelerated plan for uTREAT”

Looking back at the third quarter, it’s clear that Curasight is keeping the momentum in the development. Among other things, the much-anticipated phase II results in brain cancer were presented at the World Molecular Imaging Congress. The company now look forward to more results, while filing applications for further studies with both uTRACE and uTREAT. BioStock contacted Curasight’s CEO Ulrich Krasilnikoff to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/curasight-ceo-working-on-accelerated-plan-for-utreat/ This is a press release from BioStock -

Curasight to present at HC Andersen Capital and Stokk.io

Copenhagen, Denmark, 24 November 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q3 2023 at HC Andersen Capital and Stokk.ioThe presentation will include an update on the business progress made by the company during the first three quarters of 2023 and look ahead at the expected coming news flow. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating

Interim Report January – September 2023

Business Highlights during the third quarter 2023 · Encouraging preclinical data using uTREAT[®] in non-small cell lung cancer · Positive Phase II data reported from uTRACE[®] in brain cancer · Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress  Copenhagen, Denmark, 23 November 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – September 30, 2023. The interim report is available as an attached file to this release and on the Company’s website.

BioStock: Positive preclinical results for Curasight in lung cancer

Biotech company Curasight recently announced positive preclinical results for uTREAT in the treatment of non-small cell lung cancer, showing that uTREAT effectively inhibits tumor growth. These findings comes on the heels of recent positive preclinical results in the treatment of glioblastoma, reinforcing the hypothesis that uTREAT is not cancer type specific, but has the potential to treat a broader spectrum of solid tumors.Read the interview with Curasights CEO Ulrich Krasilnikoff at biostock.se: https://www.biostock.se/en/2023/10/positive-preclinical-results-for-curasight-in-lung-

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe